# Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study

> **NCT01251133** · PHASE3 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 122 (actual)

## Conditions studied

- Infectious Disease by Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** LBVH0101 (Hib vaccine)
- **BIOLOGICAL:** Hiberix™ Vaccine

## Key facts

- **NCT ID:** NCT01251133
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2010-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251133, "Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01251133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*